本文選題：核苷酸抗病毒 + 腎功能��； 參考：《現(xiàn)代診斷與治療》2016年24期

【摘要】：選取我院收治的慢性乙肝患者,其中拒絕使用核苷酸抗病毒藥物的作為陰性對照組,其余按給藥不同分拉米夫定(LAM)組、阿德福韋酯(ADV組)、替比夫定(LDT)組和恩替卡韋(ETV)組。比較各組患者的估算腎小球率過濾(e GFR)、血肌酐(Cr)和尿素氮(BUN)。LAM組、ETV組隊(duì)患者e GFR無明顯影響,而ADV組可降低患者e GFR,相反LDT可升高患者的e GFR,改善腎功,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。ADV組可升高患者Cr水平(P0.05),而對BUN水平無明顯影響,其余各組對Cr和BUN均無明顯影響。替比夫定可改善慢性乙型肝炎患者e GFR水平,改善腎功能,而阿德福韋酷降低e GFR,升高血肌酐水平,造成腎功能損傷。
[Abstract]:The patients with chronic hepatitis B in our hospital were selected as negative control group. The others were divided into lamivudine group, adefovir group, tibivudine group and entecavir group according to the administration of Lamivudine (Lam), tibivudine (LDT) and entecavir (ETV). Comparing the estimated glomerular rate of each group with serum creatinine (Cr) and bun BUN.LAM group, there was no significant effect on e GFR in ETV group, while ADV group could decrease the eGFR.On the contrary, LDT could increase the level of eGFR and improve renal function. The difference was statistically significant (P 0.05). ADV could increase the level of Cr and P0.05, but had no significant effect on the level of BUN, while the other groups had no significant effect on Cr and BUN. Tibivudine can improve the level of e GFR and renal function in patients with chronic hepatitis B, while adefovir can decrease the level of e GFR, increase the level of creatinine, and cause renal function damage.
【作者單位】： 東莞東華醫(yī)院感染科;
【分類號】：R512.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前6條

1 陳雪霞;;抗病毒藥物對慢性乙肝患者腎功能影響的研究[J];西北藥學(xué)雜志;2015年06期

2 連曉明;覃舒揚(yáng);莫金榮;;阿德福韋酯聯(lián)合拉米夫定與恩替卡韋單藥治療乙肝肝硬化療效比較[J];海南醫(yī)學(xué);2013年22期

3 李小溪;鐘春秀;楊淑玲;樊蓉;彭R，

本文編號：1927493